RecruitMe Clinical Trial

AN OPEN-LABEL, MULTICENTER, DOSE-ESCALATION PHASE I STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND THERAPEUTIC ACTIVITY OF RO6958688, A NOVEL T-CELL BISPECIFIC ANTIBODY THAT TARGETS THE HUMAN CARCINOEMBRYONIC ANTIGEN (CEA) ON TUMOR CELLS AND CD3 ON T CELLS, ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC CEA(+) SOLID TUMORS
A study for patients with gastrointestinal (colon, liver, pancreas, stomach) solid tumors using study drug RO6958688
Sponsor:Hoffmann-La Roche
Enrolling:Male and Female Patients
IRB Number:AAAR2410
U.S. Government ID:NCT02324257
Contact: Gulam Manji, MD: 646-317-6085 / gam2140@cumc.columbia.edu
Additional Study Information:

The purpose of this study is to find out which doses of the study drug are safe to give to patients with gastrointestinal (colon, liver, pancreas, stomach) solid tumors. The study drug is RO6958688. RO6958688 is an antibody that targets CEA on the tumor cells and may activate the immune system in targeting cancer cells. The study will also explore how the study drug works in the body and on the tumor. The study also wants to find out if RO6958688 can slow down the growth of tumors or stop the cancer.

This study is closed
Investigator
Gulam Manji, MD, PhD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Gulam Manji, MD
Email: gam2140@cumc.columbia.edu
Phone: 646-317-6085